@article{a160d329b62640b982625114dd66465f,
title = "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy",
abstract = "Some HIV-associated complications involve mitochondrial dysfunction and may be less common in individuals with iron-loading HFE (hemochromatosis gene) variants. We evaluated HFE 845A and 187G alleles in relation to mitochondrial DNA (mtDNA) levels in peripheral blood mononuclear cells from 85 individuals with HIV infection on uninterrupted antiretroviral therapy (ART) for 15 or more consecutive weeks. Carriers of HFE gene variants (N = 24) had significantly higher mtDNA levels than noncarriers (N = 61), after adjusting for age, race, sex, and type of ART [adjusted β-coefficient 297, p-value < .001 for at least one HFE variant], but mtDNA declined among all individuals on study during 48 weeks on ART. Increased cellular mtDNA content may represent a compensatory response to mitochondrial stress that is influenced by iron-loading HFE variants.",
keywords = "ART, Allele, HFE, mtDNA",
author = "Kallianpur, {Asha R.} and Mariana Gerschenson and Todd Hulgan and Harpreet Kaur and Clifford, {David B.} and Haas, {David W.} and Murdock, {Deborah G.} and McArthur, {Justin C.} and Samuels, {David C.} and Simpson, {David M.}",
note = "Funding Information: Support for these analyses was provided by NHLBI R21HL087726-03 (to AK), NIH 1P20GM113134 and 2 U54MD007601 (to MG), and NIH R21NS059330 (to TH). The primary A5117 protocol was supported by the NIAID, AI38858, AI03855, AI25903, AI27664, AI046376, AI34853, AI27658, AI27670, AI46386, AI-25859, AI46370, AI32770, and AI27668, and the Neurologic AIDS Research Consortium funded by the National Institute of Neurologic Diseases and Stroke, NS032228, NS44807, and K24 NS002253 (DMS), and GCRC Units funded by the NCRR, RR00522, RR016467, RR00044, RR-00071, and RR00051. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number UM1 AI068634, UM1 AI068636, and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: The primary A5117 protocol was supported by the NIAID, AI38858, AI03855, AI25903, AI27664, AI046376, AI34853, AI27658, AI27670, AI46386, AI-25859, AI46370, AI32770, and AI27668, and the Neurologic AIDS Research Consortium funded by the National Institute of Neurologic Diseases and Stroke, NS032228, NS44807, and K24 NS002253 (DMS), and GCRC Units funded by the NCRR, RR00522, RR016467, RR00044, RR-00071, and RR00051. Funding Information: Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number UM1 AI068634, UM1 AI068636, and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} Copyright 2018, Mary Ann Liebert, Inc., publishers.",
year = "2018",
month = nov,
doi = "10.1089/aid.2018.0025",
language = "English",
volume = "34",
pages = "942--949",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
number = "11",
}